Atorvastatin plus compound probiotics in the treatment of hyperlipidemia： clinical trials

Abstract

Objective To explore the efficacy of atorvastatin combined with compound probiotics in the treatment of hyperlipidemia. Methods From January 2019 to December 2019, 33 patients with hyperlipidemia were recruited from the People‘s Hospital of Inner Mongolia Autonomous Region and were randomly divided into the test group（n=18） and the control group（n=15） using a randomized, double-blind, controlled trial design. The 20mg atorvastatin （once a day） plus compound probiotics（once a day, 2g each time） was given in test group, and the same dose of atorvastatin plus placebo was given in control group. The blood lipid level was measured once every 4 weeks for 12 weeks to compare the blood lipid levels at each time point between two groups. Results There were no significant differences in the baseline data between two groups (P＞0.05). There were no significant differences in the levels of TC, TG, LDL-C and other blood lipid levels related to the treatment effects between two groups(P＞0.05). At the different time points, there were statistical differences in the levels of TC, TG, LDL-C and other blood lipids(P<0.05). There was no interaction between the intervention time and the two intervention methods on the levels of TC, TG, LDL-C and other blood lipids(P＞0.05). Conclusion Both atorvastatin alone and it combined with probiotics can reduce the blood lipid level in the patients with hyperlipidemia, with similar lipid-lowering efficacy.

Keywords

• probiotics
• atorvastatin
• hyperlipidemia
• randomized
• ｄouble-blind
• clinical trial